ProMIS Neurosciences Inc
TSX:PMN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ProMIS Neurosciences Inc
PP&E Net
ProMIS Neurosciences Inc
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ProMIS Neurosciences Inc
TSX:PMN
|
PP&E Net
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
PP&E Net
CA$112k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
PP&E Net
$79.6m
|
CAGR 3-Years
110%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
PP&E Net
$15.3m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
17%
|
CAGR 10-Years
23%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
PP&E Net
CA$987.1k
|
CAGR 3-Years
12%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
PP&E Net
$10.2m
|
CAGR 3-Years
198%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ProMIS Neurosciences Inc
Glance View
ProMIS Neurosciences Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario and currently employs 5 full-time employees. The company went IPO on 2005-09-30. ProMIS Neurosciences, Inc. is a Canada-based development-stage biotechnology company. The firm is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The firm is focused on the discovery engine, which is based on the use of two complementary algorithms: ProMIS and Collective Coordinates, which are used to predict targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. The firm is focused on developing antibody therapeutics for AD, ALS and PD. The firm has a wholly owned subsidiary is ProMIS Neurosciences (US) Inc. (ProMIS USA).
See Also
What is ProMIS Neurosciences Inc's PP&E Net?
PP&E Net
0
USD
Based on the financial report for Mar 31, 2023, ProMIS Neurosciences Inc's PP&E Net amounts to 0 USD.
